سعر ميتوجيكت 12.5مجم/0.25 مل سرنجة معبأة 2024

Methotrexate 12.5 mg in 0.25 ml (50 mg/ml) solution for injection in a pre-filled syringe (Metoject, Medac; Egyptian agent Sunny Medical); one syringe. The Egyptian name states i.m./i.v./s.c. use.

• Disease-modifying antirheumatic drug for severe disabling psoriasis/psoriatic arthritis and severe disabling rheumatoid arthritis where standard therapy fails; not indicated for neoplastic diseases.Population: AdultsHealth Canada Drug Product Database
• Severe active rheumatoid arthritis and polyarticular juvenile idiopathic arthritis after inadequate response to first-line therapy; severe recalcitrant disabling psoriasis; not for neoplastic diseases.Population: Adults; children with pJIADailyMed (U.S. NLM)

• Most frequent: ulcerative stomatitis, leucopenia, nausea and abdominal distress; also malaise, fatigue, chills and fever, dizziness and decreased resistance to infection.International label, same formulation · Health Canada Drug Product Database

• Hypersensitivity to methotrexate or any ingredient; severe renal impairment including end-stage renal disease.International label, same formulation · Health Canada Drug Product Database
• Pregnancy and breast-feeding.International label, same formulation · Health Canada Drug Product Database
• Alcoholism, alcoholic liver disease or other chronic liver disease; overt or laboratory evidence of immunodeficiency; pre-existing blood dyscrasias.International label, same formulation · Health Canada Drug Product Database

• Serious warning: prescribe only by physicians experienced in antimetabolite therapy; serious, possibly fatal toxic reactions (bone marrow, liver, lung, kidney, GI, skin) can occur.International label, same formulation · Health Canada Drug Product Database
• Methotrexate-induced lung disease (acute or chronic interstitial pneumonitis) may occur at any time during therapy.International label, same formulation · Health Canada Drug Product Database
• Boxed warning: severe toxic reactions including embryo-fetal toxicity and death; monitor closely for bone marrow, liver, lung, skin and kidney toxicities.International label, equivalent formulation · DailyMed (U.S. NLM)

• NSAIDsConcomitant NSAIDs are cautioned in the monograph because of the risk of increased methotrexate toxicity; use with caution.Health Canada Drug Product Database
• Proton pump inhibitors (omeprazole, esomeprazole, pantoprazole)May elevate and prolong serum methotrexate levels (mainly at high methotrexate doses); use caution.Health Canada Drug Product Database
• LeflunomideCombination may increase the risk of pancytopenia; use with caution.Health Canada Drug Product Database

• Contraindicated in pregnancy: may cause fetal death, embryotoxicity, abortion or teratogenic effects. Exclude pregnancy before starting; effective contraception during treatment and for at least 6 months to 1 year after.International label, same formulation · Health Canada Drug Product Database
• Contraindicated in pregnant women with RA or psoriasis; verify pregnancy status before starting; females use effective contraception for 6 months and males for 3 months after the final dose.International label, equivalent formulation · DailyMed (U.S. NLM)
• Contraindicated in breast-feeding mothers.International label, same formulation · Health Canada Drug Product Database

• Methotrexate: Competitively inhibits dihydrofolate reductase, blocking reduction of dihydrofolate to tetrahydrofolate and thereby DNA synthesis and cell replication.